Biomarker testing in lung cancer: from bench to bedside
Non-small-cell lung cancer (NSCLC) is the poster child of personalized medicine. With increased knowledge about biomarkers and the consequent improvement in survival rates, NSCLC has changed from being a therapeutic nihilistic disease to that characterized by therapeutic enthusiasm. The routine biom...
Saved in:
Main Authors: | Ullas Batra, Shrinidhi Nathany |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Oncology Reviews |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/or.2024.1445826/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Potentially actionable molecular alterations in particular related to poor oncologic outcomes in salivary gland carcinomas
by: Julia Pikul, et al.
Published: (2025-01-01) -
Precision oncology through next generation sequencing in hepatocellular carcinoma
by: Sayali Shinde, et al.
Published: (2025-02-01) -
New Lung Cancer Panel for High-Throughput Targeted Resequencing
by: Eun-Hye Kim, et al.
Published: (2014-06-01) -
Characterizing microbial communities and their correlation with genetic mutations in early-stage lung adenocarcinoma: implications for disease progression and therapeutic targets
by: Hao-Shuai Yang, et al.
Published: (2025-01-01) -
Validation of Customized Cancer Panel for Detecting Somatic Mutations and Copy Number Alterations
by: Su-Hye Choi, et al.
Published: (2017-12-01)